Advent Life Sciences Announces Growth of Investment Team with Three Senior Appointments
26 May 2022, London, UK: Advent Life Sciences, a leading transatlantic venture and growth investor focused on building innovative life science companies in the UK, Europe, and the US, announced today that it has appointed three senior members to its team, all sector investment specialists, and adept at building companies and supporting them in translating ideas into transformative medicines. Dominic Schmidt, based in the UK, and Satish Jindal, based in Boston, USA, have been appointed General Partners. Katrine Bosley, based in Boston, USA, joins as Venture Partner. Advent’s investment team now includes 18 professionals with a track record of nurturing entrepreneurs and companies to deliver innovative new medicines.